Press Releases

Mar 16, 2020 7:00 AM EDT Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Mar 13, 2020 7:00 AM EDT Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
Mar 11, 2020 7:30 AM EDT Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
Mar 5, 2020 7:00 AM EST Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus
Mar 3, 2020 7:00 AM EST Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson
Feb 27, 2020 6:00 AM EST Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement
Feb 24, 2020 7:00 AM EST Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications
Feb 18, 2020 7:10 AM EST Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
Feb 13, 2020 7:00 AM EST Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson
Feb 10, 2020 2:48 PM EST Can-Fite BioPharma Announces Pricing of $5 Million Public Offering

Show All

Homepage \| Contact us	only canfite.com